OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Pre… (NCT07136012) | Clinical Trial Compass
RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
United States, Australia, Canada11,000 participantsStarted 2025-08-22
Plain-language summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).
Who can participate
Age range
50 Years – 105 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥50 years
* Lp(a)≥ 200 nmol/L during screening
* Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Exclusion Criteria:
* Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
* Prior or planned arterial revascularization
* History of major bleeding disorder
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing olpasiran to prevent a first major heart event in people with high lipoprotein(a) — does my lipoprotein(a) level put me in the range where this kind of trial might even be worth discussing?
2Since this is a Phase 3 trial, there's already some earlier safety data on olpasiran — can you walk me through what's known so far about its side effect profile and whether any risks stand out for someone in my situation?
3The trial is tracking serious outcomes like heart attack, coronary death, and urgent revascularization over time, which suggests this is a long-term commitment — how long would I likely need to stay enrolled, and what would that mean for my regular care and monitoring?
4If I were to join this trial, would I still be able to take other medications or pursue standard treatments for my cardiovascular risk, or could participation limit my options in any way?
5Given that this trial is focused on preventing a first major cardiac event, is there a standard-of-care approach you'd recommend I try first, and how does that compare to what this trial is offering?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First